10-Q: RAPT Therapeutics Narrows Loss, Advances Key Programs

RAPT Therapeutics reported a reduced net loss in Q2 2025, driven by lower R&D expenses following the termination of its zelnecirnon program, while continuing development of RPT904 and tivumecirnon.

Summary

• RAPT Therapeutics, a clinical-stage immunology-based biopharmaceutical company, reported a net loss of $34.8 million for the six months ended June 30, 2025, a significant improvement from $58.2 million for the same period in 2024.
• The decrease in net loss was primarily due to a 49% reduction in research and development (R&D) expenses, which fell to $24.4 million from $47.4 million, largely attributable to the cessation of the zelnecirnon program.
• Cash and cash equivalents, along with marketable securities, totaled $168.9 million as of June 30, 2025, down from $231.0 million at December 31, 2024.
• Cash used in operating activities increased to $63.7 million for the six months ended June 30, 2025, compared to $55.2 million in the prior year, including a $35.0 million upfront license fee payment for RPT904.
• The company's lead drug candidate, RPT904, a monoclonal antibody for allergic diseases, is advancing with Phase 2 clinical trials being conducted by partner Jemincare in asthma and chronic spontaneous urticaria (CSU).
• Tivumecirnon, an oncology drug candidate, showed promising data in a Phase 1/2 trial for advanced non-small cell lung cancer (NSCLC) in combination with pembrolizumab, and the company is seeking a partner for its further development outside the Hanmi Territory.
• RAPT Therapeutics effected a 1-for-8 reverse stock split on June 16, 2025, to regain compliance with Nasdaq's minimum bid price requirement, which was achieved on June 20, 2025.
• The company believes its current cash and marketable securities are sufficient to fund operations for at least 12 months from the filing date, but anticipates needing substantial additional funding for future development and commercialization.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the net loss narrowed, this was primarily due to the termination of a significant drug program (zelnecirnon) following a serious adverse event, which is a major setback. The cash burn from operations increased, and the overall cash position significantly declined. Although there is progress with other drug candidates and a Nasdaq compliance issue was resolved, the underlying financial health and pipeline risks remain substantial, necessitating further capital raises in a challenging market.

Positives

• Net loss significantly narrowed to $34.8 million for the six months ended June 30, 2025, from $58.2 million in the prior year period.
• Research and development expenses decreased by 49% to $24.4 million, primarily due to the termination of the zelnecirnon program, which reduces future cash burn related to that specific program.
• RPT904, the lead drug candidate, is progressing with Phase 2 clinical trials for asthma and CSU being conducted by partner Jemincare, indicating advancement in the pipeline.
• Tivumecirnon, the oncology drug candidate, demonstrated greater confirmed objective response rate and progression-free survival in a Phase 2 trial when combined with pembrolizumab, suggesting potential efficacy.
• The company successfully regained compliance with Nasdaq's minimum bid price requirement following a 1-for-8 reverse stock split.

Negatives

• Cash and cash equivalents significantly decreased to $41.886 million as of June 30, 2025, from $169.735 million at December 31, 2024.
• Net cash used in operating activities increased to $63.7 million for the six months ended June 30, 2025, compared to $55.2 million in the prior year, indicating higher cash burn.
• The company incurred an accumulated deficit of $649.4 million as of June 30, 2025, reflecting continued losses since inception.
• Development of zelnecirnon, a small molecule CCR4 antagonist for inflammatory disease, was ceased in November 2024 due to an FDA clinical hold following a serious adverse event (liver failure) in a patient, representing a pipeline setback.
• Net cash provided by financing activities significantly decreased to $0.161 million for the six months ended June 30, 2025, compared to $9.737 million in the prior year, indicating less capital raised from financing activities during the period.

Risks

• Current or future product candidates may fail or suffer delays in clinical development, materially affecting commercial viability.
• The company has a history of losses and expects to continue incurring significant losses, potentially never achieving or maintaining profitability.
• There is no history of successfully developing drugs as an organization, and efforts to build a pipeline may not be successful.
• The market may not be receptive to current or potential future drug candidates, potentially preventing revenue generation from sales or licensing.
• Undesirable side effects caused by drug candidates could compromise marketability or revenue, as seen with zelnecirnon's termination due to liver failure.
• Substantial additional funds are needed to discover and advance drug candidates, and sufficient funds may not be available on acceptable terms.
• Reliance on third parties for preclinical studies, clinical trials, and manufacturing poses risks of non-performance, failure to satisfy regulatory requirements, or missed deadlines.
• Difficulties in enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Intense competition from larger, better-funded entities developing similar drug candidates could adversely affect the company's ability to commercialize.
• Inability to develop internal sales, marketing, and distribution capabilities or secure third-party agreements could prevent successful commercialization.
• International operations expose the company to business, political, operational, and financial risks, including geopolitical and macroeconomic events, and trade issues.
• Disease outbreaks, epidemics, and pandemics could materially and adversely affect business operations, including clinical trials and supply chains.
• Concentrated operations in one location (San Francisco Bay Area) expose the company to natural or other disasters.
• Inability to obtain, maintain, enforce, or defend intellectual property rights, or inadequate intellectual property rights, could impair competitive effectiveness.
• Non-compliance with U.S. and foreign anti-corruption and anti-money laundering laws can lead to criminal or civil liability.
• Significant product liability risk inherent in drug development, testing, manufacturing, and marketing, with potential for insufficient insurance coverage.
• Misconduct by employees, principal investigators, consultants, and commercial partners, including noncompliance with regulatory standards, could lead to enforcement actions.
• Stringent and evolving data privacy and security laws, regulations, and contractual obligations pose risks of investigations, litigation, fines, and business disruptions if not complied with.
• Compromised information technology systems or data could lead to adverse consequences, including regulatory actions, litigation, and reputational harm.
• Non-compliance with environmental and health and human safety laws could adversely affect the business.
• ESG matters and related reporting obligations may impact the business.
• The company's stock price may be volatile, and purchasers could incur substantial losses.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies or drug candidates.
• Principal stockholders own a significant percentage of stock, enabling them to exert significant control over corporate actions.
• As a smaller reporting company, reduced reporting requirements may make common stock less attractive to investors.
• Ability to use net operating loss carryforwards and certain other tax attributes may be subject to limitations.
• Changes in tax laws or regulations could adversely affect the business.
• No anticipated cash dividends on capital stock means capital appreciation is the sole source of gain.
• Risk of class action litigation due to stock volatility.
• Anti-takeover provisions in charter documents and Delaware law could make acquisitions more difficult.

Future Outlook

The company expects to incur substantial expenditures in the foreseeable future as it expands its pipeline and advances drug candidates through clinical development and the regulatory approval process. It anticipates needing substantial additional funding beyond its current cash and marketable securities, which are projected to last for at least 12 months from the filing date. Future funding is expected to come from equity or debt financings, strategic alliances, or other capital sources. The company acknowledges that geopolitical and macroeconomic developments could adversely affect its business, including supply chain disruptions, clinical trial delays, and challenges in raising capital.

Management Comments

• We expect to incur substantial expenditures in the foreseeable future as we expand our pipeline and advance our drug candidates through clinical development, undergo the regulatory approval process and, if our drug candidates are approved, launch commercial activities.
• We will need substantial additional funding to support our continuing operations and pursue our development strategy.
• We believe that our current cash and cash equivalents and marketable securities will provide sufficient funds to enable us to meet our obligations for at least 12 months from the filing date of this Quarterly Report on Form 10-Q.
• If such arrangements are not available at adequate levels or on acceptable terms, we would be required to significantly reduce operating expenses and delay or reduce the scope of or eliminate some of our development programs.

Industry Context

The biopharmaceutical industry is highly competitive, with numerous large pharmaceutical companies, multinational biopharmaceutical companies, and specialized biotechnology firms developing treatments for inflammatory, immunological, and oncology diseases. RAPT Therapeutics competes with companies like LongBio Pharma, United Biopharma, Yuhan (anti-IgE treatments), and Sanofi, Novartis, Otsuka, Celldex (CSU products). The industry faces significant regulatory hurdles, high development costs, and intense competition for scientific talent. Recent macroeconomic factors and geopolitical events are also noted as potential disruptors to trade, supply chains, and capital availability.

Comparison to Industry Standards

• RAPT Therapeutics' RPT904, an anti-IgE antibody, is being compared to omalizumab (Xolair), an approved anti-IgE antibody for asthma, CSU, chronic rhinosinusitis with nasal polyps, and food allergy. RPT904 demonstrated a median half-life more than two times that of omalizumab and deeper, more sustained free IgE reduction at the same dose in a Phase 1 trial conducted by Jemincare.
• Tivumecirnon's Phase 2 data in advanced checkpoint-naive NSCLC, when combined with pembrolizumab, showed greater confirmed objective response rate and progression-free survival than historical data for pembrolizumab monotherapy, suggesting a potentially competitive profile in the oncology space.
• The termination of the zelnecirnon program due to a serious adverse event (liver failure) highlights the inherent safety risks and high failure rate common in clinical-stage drug development, a challenge faced across the biopharmaceutical industry.
• The company's cash runway of at least 12 months is a common benchmark for clinical-stage biotechs, but the need for substantial additional capital aligns with the typical funding requirements for companies in this development phase, especially given the high costs of advancing drug candidates through trials.

Management Changes

Corporate Governance

Legal Proceedings

• No claims or actions are currently pending against the company that would have a material adverse effect on its results of operations, financial condition, or cash flows.

Stakeholder Impact

• **Shareholders**: Experienced dilution from past capital raises and face potential future dilution. The 1-for-8 reverse stock split impacted share count and price, aiming for Nasdaq compliance but potentially affecting liquidity. Stock price volatility remains a significant risk.
• **Employees**: A workforce reduction of approximately 40% (47 people) occurred in July 2024, impacting job security and potentially morale. New and amended stock plans (Amended ESPP, 2025 Plan, 2025 Inducement Plan) and an option repricing aim to incentivize and retain remaining talent.
• **Patients**: The cessation of the zelnecirnon program means patients who might have benefited from that therapy will not have access to it. Progress with RPT904 and tivumecirnon offers potential future therapeutic options for patients with allergic, immunological, and oncology diseases.
• **Creditors**: The company's significant accumulated deficit and ongoing need for capital indicate reliance on future funding, which could impact its ability to meet obligations if capital is not secured.
• **Partners (Jemincare, Hanmi)**: Continued collaboration with Jemincare for RPT904 development and seeking a partner for tivumecirnon are crucial for pipeline advancement and shared success.

Next Steps

• Pursue clinical development of RPT904 initially in food allergy and chronic spontaneous urticaria (CSU).
• Seek a partner to further develop tivumecirnon outside the Hanmi Territory.
• Continue pursuing different novel CCR4 antagonists believed to have improved safety margins, following the cessation of zelnecirnon development.
• Raise substantial additional capital through equity, debt financings, or strategic alliances to fund ongoing research and development and potential commercialization activities.

Key Dates

Recommendation

The company presents a mixed financial picture with a reduced net loss but increased cash burn from operations and a significant decline in overall cash reserves. The termination of the zelnecirnon program, while reducing R&D expenses, is a notable setback for the pipeline. However, the advancement of RPT904 into Phase 2 trials and promising early data for tivumecirnon provide some positive momentum. The successful Nasdaq compliance through a reverse stock split addresses an immediate listing concern. Given the ongoing need for substantial additional capital, the inherent high risks of clinical-stage drug development, and the recent pipeline setback, a 'hold' recommendation is appropriate. Investors should monitor the progress of RPT904 and tivumecirnon, the company's ability to secure additional funding on favorable terms, and its cash burn rate before considering further investment.

Keywords

Biopharmaceutical, Immunology, Oncology, Drug Development, Clinical Trials, RPT904, Tivumecirnon, SEC Filing, 10-Q, RAPT Therapeutics, CCR4 Antagonist, Monoclonal Antibody, Food Allergy, CSU, NSCLC, Financial Results, Cash Burn, Reverse Stock Split, Nasdaq Compliance